GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001623610 | Oral cavity | OSCC | macroautophagy | 192/7305 | 291/18723 | 7.01e-21 | 1.14e-18 | 192 |
GO:001050610 | Oral cavity | OSCC | regulation of autophagy | 198/7305 | 317/18723 | 1.63e-17 | 1.51e-15 | 198 |
GO:007048219 | Oral cavity | OSCC | response to oxygen levels | 200/7305 | 347/18723 | 1.17e-12 | 5.13e-11 | 200 |
GO:00162417 | Oral cavity | OSCC | regulation of macroautophagy | 96/7305 | 141/18723 | 2.33e-12 | 9.75e-11 | 96 |
GO:005507610 | Oral cavity | OSCC | transition metal ion homeostasis | 81/7305 | 138/18723 | 2.13e-06 | 2.72e-05 | 81 |
GO:007145317 | Oral cavity | OSCC | cellular response to oxygen levels | 98/7305 | 177/18723 | 7.10e-06 | 7.75e-05 | 98 |
GO:00469168 | Oral cavity | OSCC | cellular transition metal ion homeostasis | 64/7305 | 115/18723 | 2.13e-04 | 1.40e-03 | 64 |
GO:00070352 | Oral cavity | OSCC | vacuolar acidification | 17/7305 | 24/18723 | 1.59e-03 | 7.56e-03 | 17 |
GO:00362962 | Oral cavity | OSCC | response to increased oxygen levels | 20/7305 | 30/18723 | 1.99e-03 | 9.23e-03 | 20 |
GO:00550728 | Oral cavity | OSCC | iron ion homeostasis | 46/7305 | 85/18723 | 3.31e-03 | 1.42e-02 | 46 |
GO:00362954 | Oral cavity | OSCC | cellular response to increased oxygen levels | 10/7305 | 14/18723 | 1.44e-02 | 4.69e-02 | 10 |
GO:001050622 | Oral cavity | EOLP | regulation of autophagy | 74/2218 | 317/18723 | 5.84e-09 | 3.07e-07 | 74 |
GO:001623622 | Oral cavity | EOLP | macroautophagy | 65/2218 | 291/18723 | 2.74e-07 | 8.26e-06 | 65 |
GO:001624121 | Oral cavity | EOLP | regulation of macroautophagy | 38/2218 | 141/18723 | 7.18e-07 | 1.83e-05 | 38 |
GO:007048224 | Oral cavity | EOLP | response to oxygen levels | 70/2218 | 347/18723 | 5.00e-06 | 1.02e-04 | 70 |
GO:007145318 | Oral cavity | EOLP | cellular response to oxygen levels | 36/2218 | 177/18723 | 7.88e-04 | 6.25e-03 | 36 |
GO:005507624 | Oral cavity | EOLP | transition metal ion homeostasis | 27/2218 | 138/18723 | 5.80e-03 | 2.94e-02 | 27 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0019028 | Oral cavity | OSCC | Oxidative phosphorylation | 88/3704 | 134/8465 | 2.15e-07 | 1.44e-06 | 7.32e-07 | 88 |
hsa0512010 | Oral cavity | OSCC | Epithelial cell signaling in Helicobacter pylori infection | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa0414528 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa0532318 | Oral cavity | OSCC | Rheumatoid arthritis | 56/3704 | 93/8465 | 9.72e-04 | 2.76e-03 | 1.40e-03 | 56 |
hsa0511026 | Oral cavity | OSCC | Vibrio cholerae infection | 32/3704 | 50/8465 | 3.05e-03 | 7.74e-03 | 3.94e-03 | 32 |
hsa0516514 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0414212 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa00190112 | Oral cavity | OSCC | Oxidative phosphorylation | 88/3704 | 134/8465 | 2.15e-07 | 1.44e-06 | 7.32e-07 | 88 |
hsa0512017 | Oral cavity | OSCC | Epithelial cell signaling in Helicobacter pylori infection | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0515211 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa04145113 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa0532319 | Oral cavity | OSCC | Rheumatoid arthritis | 56/3704 | 93/8465 | 9.72e-04 | 2.76e-03 | 1.40e-03 | 56 |
hsa05110111 | Oral cavity | OSCC | Vibrio cholerae infection | 32/3704 | 50/8465 | 3.05e-03 | 7.74e-03 | 3.94e-03 | 32 |
hsa0516541 | Oral cavity | EOLP | Human papillomavirus infection | 79/1218 | 331/8465 | 1.96e-06 | 1.63e-05 | 9.60e-06 | 79 |
hsa0515241 | Oral cavity | EOLP | Tuberculosis | 47/1218 | 180/8465 | 2.19e-05 | 1.18e-04 | 6.96e-05 | 47 |
hsa0019045 | Oral cavity | EOLP | Oxidative phosphorylation | 36/1218 | 134/8465 | 1.05e-04 | 4.57e-04 | 2.69e-04 | 36 |
hsa0414543 | Oral cavity | EOLP | Phagosome | 38/1218 | 152/8465 | 3.42e-04 | 1.42e-03 | 8.35e-04 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP6V0A2 | SNV | Missense_Mutation | novel | c.1273N>T | p.Ala425Ser | p.A425S | Q9Y487 | protein_coding | deleterious(0.03) | possibly_damaging(0.823) | TCGA-22-4609-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATP6V0A2 | SNV | Missense_Mutation | novel | c.1315N>A | p.Gln439Lys | p.Q439K | Q9Y487 | protein_coding | tolerated(1) | benign(0.006) | TCGA-34-7107-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATP6V0A2 | SNV | Missense_Mutation | rs766224435 | c.2165C>T | p.Ala722Val | p.A722V | Q9Y487 | protein_coding | tolerated(0.21) | benign(0) | TCGA-37-A5EM-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP6V0A2 | SNV | Missense_Mutation | | c.2539N>A | p.Ser847Thr | p.S847T | Q9Y487 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-39-5016-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP6V0A2 | SNV | Missense_Mutation | | c.2540N>T | p.Ser847Leu | p.S847L | Q9Y487 | protein_coding | tolerated(0.37) | benign(0) | TCGA-39-5016-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP6V0A2 | SNV | Missense_Mutation | novel | c.806G>T | p.Arg269Leu | p.R269L | Q9Y487 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-43-2576-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ATP6V0A2 | SNV | Missense_Mutation | rs776619252 | c.604G>A | p.Val202Met | p.V202M | Q9Y487 | protein_coding | deleterious(0.03) | benign(0.311) | TCGA-43-5668-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Other, specify in notesMAGE3-AS15-NSC-003 | clinical | PD |
ATP6V0A2 | SNV | Missense_Mutation | novel | c.2211C>G | p.Ile737Met | p.I737M | Q9Y487 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-56-8626-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP6V0A2 | SNV | Missense_Mutation | | c.381N>T | p.Glu127Asp | p.E127D | Q9Y487 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-60-2715-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | PD |
ATP6V0A2 | SNV | Missense_Mutation | rs745357777 | c.775C>T | p.Arg259Trp | p.R259W | Q9Y487 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-77-8009-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |